Gendy Marie N S, Taisir Radia, Britton Emily, Costello Jean, MacKillop James
Peter Boris Centre for Addictions Research, McMaster University & St. Joseph's Healthcare Hamilton.
Department of Psychiatry and Behavioral Neurosciences, McMaster University.
Cannabis. 2025 Jul 15;8(2):141-152. doi: 10.26828/cannabis/2025/000229. eCollection 2025.
The Diagnostic and Statistical Manual of Mental Disorders version 5 (DSM-5) defines cannabis use disorder as a polythetic unidimensional diagnosis (>2 symptoms from up to 11), but few studies have empirically evaluated the latent structure of CUD. Rasch analysis is a psychometric technique that has previously been used to validate unidimensional scales, like DSM-5 CUD.
In this study, the Rasch model was used to evaluate the DSM-5 CUD criteria in a clinical sample of adults receiving inpatient treatment for substance use disorder ( = 249) reporting active cannabis use at admission. The unidimensionality of the criteria was evaluated using the Martin-Löf test and the nonparametric -T test of Ponocny. Model fit was assessed using the χ goodness of fit test for individual items.
Results supported the unidimensional structure of the criteria. Symptom # 3 was the least endorsed, highest severity item. Conversely, symptom #9 was the most endorsed and had the lowest severity estimate. Overall, the data fit the Rasch model well, although misfit was observed for symptom # 8.
Rasch's analysis of CUD symptoms in an inpatient sample broadly supports the DSM-5 CUD syndrome. Further examination is needed to determine if removing or revising the hazardous use symptom criterion in future DSM revisions would improve diagnostic measurement.
《精神疾病诊断与统计手册》第5版(DSM-5)将大麻使用障碍定义为一种多维度单维诊断(从多达11种症状中出现>2种症状),但很少有研究对大麻使用障碍的潜在结构进行实证评估。拉施分析是一种心理测量技术,此前已用于验证单维量表,如DSM-5大麻使用障碍量表。
在本研究中,拉施模型用于评估DSM-5大麻使用障碍标准,该标准应用于因物质使用障碍接受住院治疗的成年临床样本(n = 249),这些患者在入院时报告有活跃的大麻使用情况。使用马丁-洛夫检验和波诺茨尼的非参数t检验评估标准的单维度性。使用单个项目的χ²拟合优度检验评估模型拟合度。
结果支持标准的单维结构。症状#3是认可率最低、严重程度最高的项目。相反,症状#9是认可率最高、严重程度估计最低的项目。总体而言,数据与拉施模型拟合良好,尽管症状#8存在拟合不佳的情况。
对住院样本中大麻使用障碍症状的拉施分析广泛支持DSM-5大麻使用障碍综合征。需要进一步研究以确定在未来的DSM修订版中删除或修订有害使用症状标准是否会改善诊断测量。